For research use only. Not for therapeutic Use.
FTX-6746 is an orally active PPARG inhibitor. FTX-6746 shows potent tumor inhibition in mouse xenograft models[1].
FTX-6746 (3-60 mg/kg; po; twice daily for 21 d) results significant tumor suppression in UMUC9 or HT1197 xenograft model in mouse[1].
| Catalog Number | I041283 |
| CAS Number | 2829349-96-2 |
| Synonyms | 4-chloro-3-(5,7-difluoro-4-oxo-1H-quinolin-2-yl)benzonitrile |
| Molecular Formula | C16H7ClF2N2O |
| Purity | ≥95% |
| InChI | InChI=1S/C16H7ClF2N2O/c17-11-2-1-8(7-20)3-10(11)13-6-15(22)16-12(19)4-9(18)5-14(16)21-13/h1-6H,(H,21,22) |
| InChIKey | PCCCYEBARWZCEY-UHFFFAOYSA-N |
| SMILES | C1=CC(=C(C=C1C#N)C2=CC(=O)C3=C(N2)C=C(C=C3F)F)Cl |
| Reference | [1]. Mertz J, et al. Novel inhibitors of the luminal lineage transcription factor peroxisome proliferator-activated receptor gamma (PPARG) durably eradicate tumors in urothelial cancer (UC) animal models[J]. European Journal of Cancer, 2022, 174: S33-S34. |
